APA (7th ed.) Citation

Jiang, Z., Yang, Y., Zhou, J., Li, X., Meng, Q., Yu, X., . . . Bao, D. (2025). Targeting Drp1 inhibits ESCC progression via the ROS-PGC1-α-Nrf1/2 pathway. Journal of Translational Medicine, 23(1), 1. https://doi.org/10.1186/s12967-025-06697-8

Chicago Style (17th ed.) Citation

Jiang, Zhixiong, et al. "Targeting Drp1 Inhibits ESCC Progression via the ROS-PGC1-α-Nrf1/2 Pathway." Journal of Translational Medicine 23, no. 1 (2025): 1. https://doi.org/10.1186/s12967-025-06697-8.

MLA (9th ed.) Citation

Jiang, Zhixiong, et al. "Targeting Drp1 Inhibits ESCC Progression via the ROS-PGC1-α-Nrf1/2 Pathway." Journal of Translational Medicine, vol. 23, no. 1, 2025, p. 1, https://doi.org/10.1186/s12967-025-06697-8.